Technical Analysis and Summary of FDA Compliance Program 7356.002A: Sterile Drug Process Inspections
[中譯] FDA 查廠計畫 7356.002A：無菌藥品製程查核之技術分析與摘要

1. PART I: BACKGROUND AND PROGRAM SCOPE
[中譯] 1. 第一部分：背景與計畫範圍

Compliance Program 7356.002A represents the FDA’s primary strategic instrument for safeguarding the integrity of the sterile drug supply chain.
[中譯] 查廠計畫 7356.002A 是 FDA 確保無菌藥品供應鏈完整性的主要策略工具。

As a Senior Regulatory Compliance Consultant, I view this document not merely as a manual, but as the mandatory technical framework that investigators must use to identify the root causes of microbial contamination.
[中譯] 身為資深法規合規顧問，我認為這份文件不僅是一本手冊，更是稽核員用以找出微生物污染根本原因的強制性技術框架。

Given that the administration of non-sterile parenteral products can result in immediate morbidity or death, this program serves as the regulatory foundation for ensuring that manufacturers operate within a rigorous "state of control."
[中譯] 鑑於施打未達無菌標準的注射劑產品可能導致立即的疾病或死亡，此計畫成為確保製造商在嚴格的「管制狀態」下營運的法規基石。

The scope of this program is absolute, encompassing the manufacture and testing of all sterile drug products.
[中譯] 該計畫的範圍是絕對的，涵蓋所有無菌藥品產品的製造與測試。

This includes products sterilized via filtration, aseptic assembly, or terminal sterilization.
[中譯] 這包括透過過濾滅菌、無菌組裝或終端滅菌處理的產品。

Coverage explicitly includes sterile bulk drugs (APIs), ophthalmic drugs, otic dosage forms , and both small volume parenterals (SVPs) and large volume parenterals (LVPs).
[中譯] 其涵蓋範圍明確包含無菌原料藥 (API)、眼用藥物、耳用劑型，以及小容量注射劑 (SVP) 與大容量注射劑 (LVP)。

Note that while this program applies to small molecule and licensed biological therapeutic drug products, it explicitly excludes veterinary products and biological products regulated by the Center for Biologics Evaluation and Research (CBER).
[中譯] 請注意，雖然此計畫適用於小分子與已獲許可的生物治療藥品，但明確排除動物用藥品以及由生物製劑評估與研究中心 (CBER) 管轄的生物製品。

A critical distinction must be maintained between guidance and law.
[中譯] 必須在「指引」與「法律」之間保持關鍵的區分。

The "2004 Aseptic Processing Guidance" provides the FDA’s current technical expectations, yet it holds no legal weight.
[中譯] 「2004 無菌製程指引」提供了 FDA 當前的技術期望，但其本身不具備法律效力。

The sole legal basis for all inspectional observations (FDA Form 483) and subsequent enforcement actions remains the Current Good Manufacturing Practice (CGMP) regulations in 21 CFR Parts 210 and 211. While manufacturers may utilize alternative technical approaches, they bear the burden of proving such methods satisfy the stringent requirements of the CFR.
[中譯] 所有查廠缺失觀察（FDA 483 表格）與後續執法行動的唯一法律依據，仍是 21 CFR Parts 210 與 211 中的現行優良製造規範 (CGMP)。雖然製造商可採用替代技術方法，但他們必須承擔證明這些方法符合 CFR 嚴格要求的舉證責任。

This regulatory framework establishes the mandate for the standardized implementation and strategic objectives detailed below.
[中譯] 此法規框架確立了下述標準化實施與策略目標的強制性。

--------------------------------------------------------------------------------

2. PART II: IMPLEMENTATION AND STRATEGIC OBJECTIVES
[中譯] 2. 第二部分：實施與策略目標

The implementation of this program necessitates a standardized, high-intensity approach to sterile drug inspections.
[中譯] 本計畫的實施需要對無菌藥品查廠採取標準化、高強度的方法。

Uniformity across the investigator cadre is essential to prevent "regulatory arbitrage" and to ensure that high-risk manufacturing technologies—regardless of geography—are scrutinized against the same benchmarks of sterility assurance.
[中譯] 確保所有稽核員之間的統一性至關重要，以防止「法規套利」，並確保無論地理位置為何，高風險製造技術都受到相同的無菌保證基準審查。

The program is structured around four primary strategic objectives (per Section 2.1):
[中譯] 該計畫圍繞四項主要策略目標構建（依據 2.1 節）：

Determine CGMP Compliance: Evaluate whether manufacturers of sterile bulk and finished dosage forms operate in accordance with 21 CFR Parts 210 and 211.
[中譯] 確認 CGMP 合規性：評估無菌原料藥與成品劑型的製造商，其營運是否符合 21 CFR Parts 210 與 211 的規範。

Identify Sterility Risks: Scrutinize specific operations impacting sterility to identify areas where manufacturers must implement immediate corrective and preventive actions (CAPA).
[中譯] 識別無菌風險：嚴密審查影響無菌性的特定操作，以找出製造商必須立即實施矯正與預防措施 (CAPA) 的領域。

Evaluate Industry CGMPs: Assess the current state of good manufacturing practices across the sterile drug industry to inform future policy and risk models.
[中譯] 評估業界 CGMP 現況：評估無菌藥品產業的現行優良製造規範狀態，以為未來的政策與風險模型提供參考。

Initiate Enforcement Actions: Provide the evidentiary basis for regulatory action against manufacturers failing to maintain a state of control.
[中譯] 啟動執法行動：為無法維持管制狀態的製造商，提供法規裁罰行動所需的證據基礎。

The FDA employs a "System-based Inspection Strategy," where the District Office selects systems for coverage based on the firm’s specific risk profile and compliance history.
[中譯] FDA 採用「系統導向查廠策略」，由區間辦公室根據公司的特定風險特徵與合規歷史，選擇要涵蓋的系統。

For this program, findings in the Quality System are non-negotiable and serve as the barometer for the entire facility.
[中譯] 在本計畫中，品質系統的稽核發現是毫無妥協餘地的，並作為整個設施合規狀態的晴雨表。

The following table summarizes the mandatory requirements and triggers for inspectional depth:
[中譯] 下表總結了查廠深度的強制性要求與觸發條件：

Criteria [中譯] 評估基準	Full Inspection (PAC 56002A) [中譯] 完整查核	Abbreviated Inspection (PAC 56002I) [中譯] 簡化查核
Mandatory Scope [中譯] 強制範圍	Must cover Quality, Facilities & Equipment, and Production Systems (minimum of four systems total). [中譯] 必須涵蓋品質、廠房與設施、以及生產系統（總計至少涵蓋四個系統）。	Focuses on microbial controls and sterility assurance; specific critical system elements. [中譯] 聚焦於微生物管制與無菌保證；針對特定關鍵系統元素進行審核。
Primary Trigger [中譯] 主要觸發條件	Initial inspections; follow-ups to Warning Letters or OAI status; significant operational changes. [中譯] 首次查廠；針對警告信或 OAI 狀態的後續追蹤；營運發生重大變更。	Sustained compliance history; modern risk management (ICH Q9) implementation. [中譯] 具備良好的持續合規紀錄；已落實現代化風險管理 (ICH Q9) 機制。
Compliance History [中譯] 合規歷史	History of recurring violations, fluctuating compliance, or significant recalls. [中譯] 具有反覆違規、合規狀態不穩定的歷史，或曾發生重大回收事件。	Two consecutive NAI or no more than one VAI inspection with no Class 1 recalls. [中譯] 連續兩次獲得 NAI 或最多一次 VAI 查核結果，且無 Class 1 回收事件。
Data Scrutiny [中譯] 數據審查深度	Comprehensive baseline review of all systems to determine a "state of control." [中譯] 對所有系統進行全面的基準審查，以判定是否處於「管制狀態」。	Deep-dive into sterility data (media fills, EM, sterility failures) since the last Full Inspection. [中譯] 深入追查自前次完整查核以來的無菌數據（如培養基模擬充填、環境監控、無菌測試失敗紀錄）。

This high-level strategy translates into granular shop-floor scrutiny, beginning with the specific sterilization methodologies utilized.
[中譯] 這種高階策略轉化為車間現場的精細審查，首先從所使用的特定滅菌方法開始。

--------------------------------------------------------------------------------

3. PART III: INSPECTIONAL METHODOLOGY AND SYSTEM COVERAGE
[中譯] 3. 第三部分：查廠方法學與系統涵蓋範圍

Operational risk in sterile manufacturing is bifurcated: terminal sterilization (preferred for its higher assurance level) and aseptic processing (inherently high-risk due to manual interventions).
[中譯] 無菌製造的操作風險分為兩類：終端滅菌（因其較高的無菌保證等級而較受青睞）與無菌製程（因涉及人工作業介入而具備先天高風險）。

Auditors must prioritize lines where human interaction is most frequent, as the operator remains the primary vector for contamination.
[中譯] 稽核員必須優先審查人為介入最頻繁的生產線，因為操作人員始終是污染的主要媒介。

3.1 Sterilization Methods and Operational Risks
[中譯] 3.1 滅菌方法與操作風險

Terminal sterilization cycles are evaluated as either "Overkill"—designed to destroy the bioburden regardless of initial resistance—or "Bioburden Based."
[中譯] 終端滅菌週期被評估為「過度殺菌 (Overkill)」（無論初始抗性為何，皆設計為徹底摧毀生物負載）或「基於生物負載 (Bioburden Based)」。

The latter requires a sophisticated understanding of environmental isolates and their heat resistance.
[中譯] 後者需要對環境分離菌及其耐熱性有非常深入的理解。

Conversely, aseptic processing is the most vulnerable methodology, where the lack of ISO 5 continuity during manual manipulations is a frequent trigger for Official Action Indicated (OAI) recommendations.
[中譯] 相反地，無菌製程是最脆弱的方法，在人工作業介入期間若無法維持 ISO 5 的連續性，往往是觸發「官方指示行動」(OAI) 建議的常見原因。

3.2 Critical System Scrutiny
[中譯] 3.2 關鍵系統嚴密審核

Quality System (Section 3.5): Scrutinize the Quality Unit’s ability to react to trends.
[中譯] 品質系統（第 3.5 節）：嚴密審查品質部門對趨勢的反應能力。

Mandatory data points for review include all sterility test failures (regardless of final disposition), media fill failures, and WFI excursions.
[中譯] 強制審查的數據點包含所有無菌測試失敗（無論最終判定為何）、培養基模擬充填失敗，以及注射用水 (WFI) 超標事件。

Facilities and Equipment System (Section 3.6): Evaluate cleanroom design and HEPA filtration.
[中譯] 廠房與設施系統（第 3.6 節）：評估無塵室設計與 HEPA 過濾系統。

For Lyophilizers , focus on the high-risk transition of partially stoppered vials.
[中譯] 針對冷凍乾燥機，應重點關注半打塞西林瓶轉移時的高風險過程。

For Isolators/RABS , challenge the decontamination validation (e.g., 6-log BI reduction) and the frequency of glove integrity testing.
[中譯] 針對隔離系統/RABS，挑戰其消毒確效（如 6-log 生物指示劑減菌）以及手套完整性測試的頻率。

Materials System (Section 3.7): Audit Water for Injection (WFI) systems for "dead legs" and non-sanitary fittings.
[中譯] 物料系統（第 3.7 節）：稽核注射用水 (WFI) 系統中的「盲管」與非衛生級管件。

Evaluate container-closure integrity (CCI) data to ensure the system prevents ingress throughout the product’s shelf life.
[中譯] 評估容器封閉完整性 (CCI) 數據，以確保系統在產品效期內能防止外部侵入。

Production System (Section 3.8): Media fills are the ultimate validation tool. They must simulate "worst-case" durations and all shifts.
[中譯] 生產系統（第 3.8 節）：培養基模擬充填是終極的確效工具。必須模擬「最差情況」的時間長度與涵蓋所有班別。

Auditors must observe real-time aseptic techniques; any break in the critical zone must be documented as a CGMP failure.
[中譯] 稽核員必須實地觀察即時的無菌操作技術；任何在關鍵區域內的違規行為都必須記錄為 CGMP 缺失。

Laboratory Control System (Section 3.10): Scrutinize the efficacy of disinfectants against resident flora.
[中譯] 實驗室管制系統（第 3.10 節）：嚴密審查消毒劑針對環境常駐菌群的有效性。

Personnel monitoring must occur after every significant intervention and upon cleanroom exit.
[中譯] 在每次重大介入操作後以及離開無塵室時，都必須進行人員監控。

The analytical laboratory serves as the final, albeit limited, barrier to distributing non-sterile products.
[中譯] 分析實驗室是防堵未達無菌標準產品出廠的最後一道防線，儘管其防護能力有限。

--------------------------------------------------------------------------------

4. PART IV: ANALYTICAL REQUIREMENTS
[中譯] 4. 第四部分：分析要求

Standardized laboratory testing is the final checkpoint. Because microbial contamination is often heterogeneous and low-level, the accuracy of these tests is critical.
[中譯] 標準化實驗室測試是最後的檢查點。由於微生物污染通常具異質性且含量低，因此這些測試的準確性至關重要。

Sterility Testing: Must strictly adhere to USP <71> and the FDA’s Sterility Analytical Manual (SAM).
[中譯] 無菌測試：必須嚴格遵守 USP <71> 與 FDA 的無菌分析手冊 (SAM)。

Any positive result must be treated as a systemic failure unless laboratory error is unequivocally proven.
[中譯] 除非能明確證明是實驗室失誤，否則任何陽性結果都必須視為系統性失效。

Bacterial Endotoxin Testing (BET): Must follow USP <85>.
[中譯] 細菌內毒素測試 (BET)：必須遵守 USP <85>。

Auditors must verify that the BET methodology is validated for each specific product to ensure no inhibition or enhancement.
[中譯] 稽核員必須確認每個特定產品的 BET 方法皆經過確效，以確保不存在干擾（抑制或增強）。

Particulate Matter: Injectables must be analyzed per USP <78> to ensure they are free from foreign matter that could cause patient harm.
[中譯] 微粒物質：注射劑必須依照 USP <78> 進行分析，確保其不含可能導致病患傷害的異物。

These analytical findings are integrated into the broader regulatory enforcement strategy.
[中譯] 這些分析發現將被整合到更廣泛的法規執法策略中。

--------------------------------------------------------------------------------

5. PART V: REGULATORY AND ADMINISTRATIVE STRATEGY
[中譯] 5. 第五部分：法規與行政管理策略

The FDA balances consumer protection against the risk of drug shortages.
[中譯] FDA 在保護消費者與藥品短缺風險之間尋求平衡。

However, the agency will pursue enforcement independently of physical sample results if CGMP documentation demonstrates a loss of control.
[中譯] 然而，若 CGMP 文件紀錄顯示藥廠已失去管制能力，即使實體樣品測試無異常，該機構仍會獨立採取執法行動。

5.1 Deficiencies Warranting Regulatory Action
[中譯] 5.1 構成法規裁罰行動的缺失項目

Actual Contamination: Filth or microbes found in product. Risk: Direct patient harm or death.
[中譯] 實際污染：產品中發現髒污或微生物。風險：直接導致病患傷害或死亡。

Failure to Meet Label Claims: Non-conformance to NDA/ANDA/USP. Risk: Sub-potency or chemical instability.
[中譯] 未達標示宣稱：不符合 NDA/ANDA/USP 規範。風險：效力不足或化學不穩定性。

Violative Distribution: Releasing non-conforming product. Risk: Intentional distribution of adulterated drugs.
[中譯] 違規經銷：放行不合格產品。風險：蓄意散佈劣藥。

Lack of Sterilization Validation: Unproven cycle efficacy. Risk: Release of non-sterile units due to unvalidated cycles.
[中譯] 缺乏滅菌確效：滅菌週期效能未經證實。風險：因使用未經確效的週期而釋放非無菌單位。

Inadequate Media Fills: Failure to simulate production risks. Risk: Undetected aseptic process failures.
[中譯] 培養基模擬充填不足：未能有效模擬生產風險。風險：無菌製程失效未能被察覺。

Poor Investigations: Inadequate review of failures/excursions. Risk: Recurrence of systemic contamination.
[中譯] 偏差調查不佳：對失敗/超標事件審查不充分。風險：系統性污染反覆發生。

Inadequate Facility Design: Poor protection of sterile components. Risk: Environmental ingress into "sterile" zones.
[中譯] 廠房設計不良：對無菌組件的防護極差。風險：環境污染物侵入「無菌」區域。

Weak Disinfection Program: Ineffective sporicidal agents. Risk: Proliferation of resistant microbes in cleanrooms.
[中譯] 消毒計畫薄弱：殺孢子劑無效。風險：具抗性的微生物在無塵室內滋生。

WFI System Failure: Water failing chemical/endotoxin specs. Risk: Introduction of pyrogens into the product stream.
[中譯] 注射用水系統失效：水質未能達到化學/內毒素規格。風險：熱原被導入產品流中。

Poor Employee Practices: High-risk aseptic techniques. Risk: Human-derived microbial contamination of the critical zone.
[中譯] 員工操作規範不佳：具備高風險的無菌操作。風險：關鍵區域受到人源性微生物污染。

Lack of Training: Unqualified personnel in critical roles. Risk: Human error during sterilization or filling operations.
[中譯] 缺乏培訓：關鍵崗位人員不合格。風險：滅菌或充填操作過程中發生人為失誤。

Inadequate 100% Inspection: Failure to detect particulates/leaks. Risk: Distribution of units with compromised seals or filth.
[中譯] 不充分的 100% 全檢：未能檢測出微粒/洩漏。風險：散佈封閉性受損或含有髒污的單位。

Incomplete Batch Records: Missing EM/interventions data. Risk: Release of batches without full quality oversight.
[中譯] 批次紀錄不完整：遺漏環境監控 (EM)/介入操作數據。風險：在未具備完整品質監督的情況下放行批次。

Invalid Test Methodology: Unvalidated sterility/BET tests. Risk: False negative results masking contaminated lots.
[中譯] 無效的測試方法：無菌/BET 測試未經確效。風險：偽陰性結果掩蓋了受污染的批次。

Inadequate EM Program: Lack of dynamic monitoring. Risk: Undetected microbial blooms during production.
[中譯] 環境監控計畫不充分：缺乏動態監控。風險：生產過程中微生物暴增卻未被察覺。

Inadequate PM Program: Failure to monitor gloves/gowns. Risk: Release of product handled by contaminated operators.
[中譯] 人員監控計畫不充分：未能監控手套/無塵服。風險：放行由受污染作業員處理的產品。

Official Action Indicated (OAI) status is recommended when these deficiencies demonstrate that management is unwilling or unable to maintain a state of control.
[中譯] 當這些缺失證明管理層不願意或無法維持管制狀態時，將建議給予官方指示行動 (OAI) 狀態。

--------------------------------------------------------------------------------

6. PART VI & VII: REFERENCES AND CENTER RESPONSIBILITIES
[中譯] 6. 第六與第七部分：參考文獻與中心職責

The program utilizes a rigorous framework of industry and regulatory references:
[中譯] 該計畫利用了產業與法規參考文獻的嚴謹框架：

Regulatory: 21 CFR 210/211; FDA 2004 Aseptic Processing Guidance.
[中譯] 法規：21 CFR 210/211；FDA 2004 無菌製程指引。

Technical: PDA Technical Reports (No. 1, 22, 26, 28, 51); ISO Standards (14644, 17665, 14698).
[中譯] 技術：PDA 技術報告（第 1, 22, 26, 28, 51 號）；ISO 標準 (14644, 17665, 14698)。

Analytical: USP <71>, <85>, <78>.
[中譯] 分析：USP <71>, <85>, <78>。

The CDER Office of Product Quality (OPQ) reviews all enforcement recommendations.
[中譯] CDER 藥品品質辦公室 (OPQ) 負責審查所有執法建議。

In cases where enforcement threatens the supply of medically necessary drugs, the CDER Drug Shortage Staff is engaged to manage the supply-safety balance.
[中譯] 在執法行動威脅到醫療必要藥品供應的情況下，將由 CDER 藥品短缺處理專員介入，以管理供應與安全之間的平衡。

--------------------------------------------------------------------------------

7. ATTACHMENT A: INSPECTIONAL POINTS TO CONSIDER (TECHNICAL CHECKLIST)
[中譯] 7. 附錄 A：查廠考量要點（技術查檢表）

7.1 Sterilization and Validation Audit Guide
[中譯] 7.1 滅菌與確效稽核指南

Moist Heat Sterilization: Challenge the firm’s "cold spot" determination.
[中譯] 濕熱滅菌：挑戰該公司對「冷點 (cold spot)」的判定結果。

Verify that probe placement in heat distribution studies represents the actual worst-case load configuration documented in the NDA/ANDA.
[中譯] 確認熱分佈研究中的探頭放置位置，是否能代表 NDA/ANDA 文件中記錄的實際最差情況負載配置。

Inspect for clean steam usage to prevent endotoxin introduction.
[中譯] 檢查是否使用純蒸汽，以防止內毒素的引入。

Dry Heat/Depyrogenation: Verify HEPA integrity testing frequency is increased to account for thermal stress (>360°C) in tunnels.
[中譯] 乾熱滅菌/去熱原：確認 HEPA 完整性測試的頻率已提高，以應對烘箱隧道內的熱壓力 (>360°C)。

Challenge the 3-log endotoxin reduction validation; ensure endotoxin was dried on the carrier before the challenge.
[中譯] 挑戰 3-log 內毒素減滅確效；確保在挑戰測試之前，內毒素已在載體上乾燥。

Aseptic Filling Validation: Confirm media fills incorporate all shifts and the maximum commercial production duration.
[中譯] 無菌充填確效：確認培養基模擬充填涵蓋了所有班別以及最長商業生產時間。

Observe if "atypical" interventions (e.g., pump changes) seen on the floor are validated in media fills.
[中譯] 觀察車間現場看到的「非典型」介入操作（例如更換幫浦），是否已經在培養基模擬充填中經過確效。

Lyophilization: Inspect for ISO 5 continuity during the transport of partially stoppered vials.
[中譯] 冷凍乾燥：檢查半打塞西林瓶運輸過程中的 ISO 5 環境連續性。

Verify the sterility of the gas used to break the vacuum and the validation of the SIP cycle for the chamber.
[中譯] 確認用於破除真空的氣體的無菌性，以及腔體在位滅菌 (SIP) 週期的確效結果。

Isolator Technology: Challenge the 6-log reduction validation of BIs at obstructed locations.
[中譯] 隔離設備技術：挑戰位於阻擋區域的生物指示劑 (BI) 6-log 減滅確效。

Verify that glove integrity testing is performed with sufficient frequency to detect micro-leaks.
[中譯] 確認手套完整性測試執行的頻率是否足以檢測出微小洩漏。

7.2 Monitoring and Personnel Audit Guide
[中譯] 7.2 監控與人員稽核指南

Environmental Monitoring (EM): Observe if sampling occurs at work height during dynamic conditions.
[中譯] 環境監控 (EM)：觀察動態條件下取樣點是否位於工作高度。

Challenge the rationale for sampling locations; they must be in the highest-risk areas of the critical zone.
[中譯] 挑戰取樣位置的合理性；它們必須位於關鍵區域中風險最高的點。

Personnel Monitoring (PM): Verify that monitoring occurs after significant interventions and upon cleanroom exit.
[中譯] 人員監控 (PM)：確認在重大介入操作後以及離開無塵室時進行監控。

Inspect gowns to ensure they are non-shedding and provide a total microbial barrier.
[中譯] 檢查無塵服，以確保其不發塵並能提供完全的微生物屏障。

Final Summary: A holistic, risk-based approach to sterile drug process inspections is the only defense against systemic quality failures.
[中譯] 最終總結：對無菌藥品製程查核採取全面且以風險為基礎的方法，是防禦系統性品質失效的唯一手段。

Investigators must maintain a high level of technical skepticism, focusing on the points of human intervention and the validation of sterilization cycles, to ensure every distributed unit is safe for patient use.
[中譯] 稽核員必須保持高度的技術懷疑態度，將重點放在人工作業介入點與滅菌週期的確效上，以確保每一批出廠的產品都能安全地用於病患。